Posts by Steven Chervenick
A New Study is Looking at the Combination of Keytruda and ONCOS-102
A new combination of two existing drugs is being tested to treat mesothelioma. Merck and Targovax, which have the drugs Keytruda (pembrolizumab), an immunotherapy drug, and ONCOS-102, a modified adenovirus, are working together in the study. They can both be used on their own alongside chemotherapy to treat mesothelioma, but the results are not great.…
Read MoreHigh Resolution Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
Primary Outcome Measures Prospectively gather information related to the use of high-resolution computed tomographic imaging (HRCT) including photon counting CT (PCCT) scans, together with minimally invasive surveillance for early detection of mesotheliomas in pts with … [ Time Frame: annual or bi-annual followup, 5 years interim analysis ] Documentation of the counts, incidence, and frequencies…
Read MoreChemoperfusion Could help Extend Mesothelioma Sufferers’ Lives
Mesothelioma is a deadly cancer of the mesothelium, which lines the lungs, heart, abdomen, and tunica vaginalis testis after exposure to asbestos. The most common type is pleural mesothelioma, which affects the lining of the lungs. There is no cure, so the best option for people with this cancer is undergoing clinical trials that help…
Read MoreEfficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma (TALAMESO)
Primary Outcome Measures Non-progression proportion [ Time Frame: 6 month after starting talazoparib ] The non-progression proportion is defined as the proportion of patients free of progression 6 months after talazoparib start. Disease progression will be based on (i) tumor assessment made by the investigators according to the RECIST 1.1 criteria and/or, ii) non-equivocal…
Read MoreThe Protein Inhibitor Tazemetostat Could Soon Treat Mesothelioma
Mesothelioma could soon be treated by tazemetostat, a new protein inhibitor. Research groups at the American Society of Clinical Oncology made presentations speaking about the effectiveness of the drug on different cancers, with one of them being mesothelioma. It was shown to be effective, and could eventually be a second-line treatment. It is not a…
Read MoreA Combination of Immunotherapy Drugs Could Help Mesothelioma Patients
Mesothelioma is an incurable cancer of the mesothelium resulting from asbestos exposure. Many clinical trials have been found to help patients but there is still no cure. People primarily have pleural mesothelioma where the linings of the lungs have cancer, but it can also affect the lining of the abdomen (peritoneal), lining of the heart…
Read MoreCryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma
Primary Outcome Measures Local tumor infiltration by cytotoxic cluster of differentiation 8 positive (CD8+) cells [ Time Frame: After cryoablation of mesothelioma up to 1 year ] Will be tested by cryoablating a small region of tumor at the time of pleural biopsy. Preponderance of T cells in ablated tumor tissue in comparison to non-cryoablated tissue [ Time Frame: Up to 1…
Read MoreKeytruda is Now Approved for Mesothelioma and Other Cancers
Keytruda is now approved for certain mesothelioma patients. The immunotherapy drug has been tested for mesothelioma before, but has not been approved for the treatment of it. The approval is for adult and pediatric cancers with unresectable disease and high mutational burden that have been treated and have no other treatment options available. Unfortunately, there…
Read MoreHalofuginone Could Soon be Used to Treat Mesothelioma
Mesothelioma is a devastating cancer that primarily affects the lining of the lungs and abdomen. Once exposed to asbestos, it can take years to develop and after being diagnosed, there are not many options for patients. Since there is not a cure, clinical trials can give people hope and can potentially help extend their lives.…
Read More177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (LuPARP)
Primary Outcome Measures Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: up to 6 months after last treatment cycle ] To assess the number of participants with toxicity of 177Lu-DOTA-TATE in combination with olaparib measured by NCI Common Toxicity Criteria v 5.0 Secondary Outcome Measures TTP [ Time Frame: 3 years ] Time to progression Response…
Read More